Physician

Tarek Eldawy, M.D.

According to 2025 Medicare claims, Tarek Eldawy, M.D. (NPI: 1669416459) practices hematology/oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Seminole, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32701-5621. Eldawy is affiliated with the Gulf Coast Health Partners (ACO ID: A2299) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Eldawy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 848 traditional Medicare patients, billed 187,086 HCPCS/CPT codes, and received $3,388,819 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,066 prescription claims across 214 beneficiaries totaling $3,437,633 in drug costs, led by Revlimid (Lenalidomide). DME data shows 41 claims. Open Payments data shows 252 records totaling $8,631. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $120,506 to $3,388,819. Similarly, Part D prescription costs have risen steadily, from $656,794 to $3,437,633. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $26,322 to $2,227.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	452	1,972	$120,506
2016	457	1,965	$121,026
2017	514	2,111	$130,098
2018	564	2,145	$132,465
2019	561	2,114	$135,840
2020	610	1,939	$115,697
2021	556	1,909	$146,923
2022	809	1,956	$136,348
2023	755	31,535	$561,138
2024	848	187,086	$3,388,819

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	191	1,790	$656,794
2016	196	1,958	$1,136,921
2017	239	2,245	$1,746,770
2018	239	2,028	$2,300,020
2019	242	1,752	$1,602,803
2020	247	2,029	$2,638,031
2021	260	2,038	$2,746,587
2022	230	1,643	$2,422,556
2023	236	1,426	$2,395,648
2024	214	1,066	$3,437,633

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	68	236	$37,302
2016	39	173	$25,759
2017	N/R	40	$2,219
2018	N/R	N/R	N/R
2019	N/R	22	$1,938
2020	N/R	83	$3,142
2021	N/R	26	$1,510
2022	N/R	84	$3,741
2023	N/R	82	$3,539
2024	N/R	41	$842

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	323	865	$99
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	367	555	$65
96372	Injection of drug or substance under skin or into muscle	234	797	$11
36415	Insertion of needle into vein for collection of blood sample	532	1,537	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	516	1,468	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	76	2,016	$1,331,303
Xtandi	Enzalutamide	38	1,140	$463,351
Calquence	Acalabrutinib Maleate	15	450	$181,623
Venclexta	Venetoclax	13	386	$143,570
Eliquis	Apixaban	78	3,287	$63,362

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk	Y	N/R	11	$464
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$191
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	15	$188

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	252	$8,631	Ipsen Biopharmaceuticals, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Tarek Eldawy, M.D.?

Tedicare shows public-source Medicare data for Tarek Eldawy, M.D. (NPI 1669416459), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Tarek Eldawy, M.D. have ACO affiliation data?

Tarek Eldawy, M.D. is shown with ACO affiliation data for Gulf Coast Health Partners (MSSP, ACO ID A2299) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Tarek Eldawy, M.D.?

Tarek Eldawy, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Tarek Eldawy, M.D. have Open Payments data?

Tarek Eldawy, M.D. has 252 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.